{"gene":"SLC6A3","run_date":"2026-06-10T07:46:34","timeline":{"discoveries":[{"year":2001,"finding":"The 9-repeat VNTR in the 3' untranslated region of the human DAT gene (SLC6A3) functions as a transcriptional enhancer in dopamine neurons, demonstrated by lipid transfection into an immortalized dopaminergic cell line and biolistic transfection into dopamine neurons in neonatal rat midbrain slices.","method":"Lipid transfection and biolistic transfection reporter assays in dopaminergic cell lines and primary dopamine neurons","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal transfection systems (cell line + primary neurons), single lab","pmids":["11739616"],"is_preprint":false},{"year":2003,"finding":"DAT phosphorylation is regulated by PI3K, PKC, and MEK1/2 kinase cascades through phosphoacceptor sites concentrated in the N-terminus of DAT; specific N-terminal serine/threonine residues (S7 for PKC; T62, S581, T612 for PI3K; S12, T595 for MEK1/2) are required for kinase-dependent regulation of DAT surface expression and dopamine uptake Vmax, confirmed by 32P-labeling studies.","method":"Site-directed mutagenesis of 20 DAT N-terminal phosphoacceptor sites combined with pharmacological kinase inhibitors/activators, dopamine uptake assays, and 32P-labeling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro mutagenesis at 20 sites combined with biochemical assays and radioisotope labeling, multiple orthogonal methods in single rigorous study","pmids":["12660249"],"is_preprint":false},{"year":2010,"finding":"Activation of Gq-coupled receptors (group I metabotropic glutamate receptors in rat substantia nigra slices; muscarinic receptors in DAT-expressing cell line) induces DAT-mediated dopamine efflux (reverse transport) through a PKC-dependent mechanism, as shown by amperometry/HPLC measurements inhibited by DAT antagonists.","method":"Amperometry in rat brain slices, HPLC in cell lines, pharmacological activation/inhibition of Gq-coupled receptors and PKC","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — two independent experimental systems (brain slices + cell line), specific pharmacological controls, mechanistically defined PKC link","pmids":["20477913"],"is_preprint":false},{"year":2014,"finding":"The autism/ADHD-associated DAT coding variant A559V (hDAT A559V) is hyper-phosphorylated at N-terminal serine residues, is resistant to amphetamine-induced cell surface redistribution (trafficking), exhibits constitutively elevated PKCβ activity, and lacks amphetamine-induced dopamine efflux. Pharmacological inhibition of PKCβ or Ala substitution of the five N-terminal serines restores AMPH-induced trafficking and DA efflux.","method":"Cell surface biotinylation/trafficking assays, PKCβ activity assays, N-terminal serine mutagenesis, dopamine efflux measurements in transfected cells","journal":"Translational psychiatry","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis, pharmacological rescue, multiple orthogonal biochemical readouts in single rigorous study","pmids":["25313507"],"is_preprint":false},{"year":2015,"finding":"The Rho-family guanine nucleotide exchange factor Vav2 is required for GDNF/Ret-dependent regulation of DAT cell surface expression and transport activity selectively in nucleus accumbens dopamine terminals; Vav2-/- and Ret-/- mice show elevated DAT activity with increased intracellular DA and reduced cocaine behavioral response.","method":"Genetic knockout mouse models (Vav2-/-, Ret-/-), DAT surface expression assays, dopamine measurements, behavioral cocaine response","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in two independent KO mouse lines, combined with biochemical and behavioral readouts, demonstrating in vivo pathway position","pmids":["26147533"],"is_preprint":false},{"year":2017,"finding":"A peptide (DAT-S1) that disrupts the D2 receptor–DAT protein complex inhibits DAT cell surface expression and protects dopaminergic neurons against dopamine neurotoxicity by inhibiting caspase-3 and PARP-1 cleavage; this demonstrates that the D2R–DAT complex regulates DAT surface expression and thereby dopamine reuptake and intracellular dopamine levels.","method":"Interfering peptide disruption of D2R-DAT complex, cell surface expression assay, caspase-3/PARP-1 cleavage assay, neurotoxicity assay","journal":"Experimental neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — peptide disruption with multiple downstream biochemical readouts, single lab","pmids":["28579325"],"is_preprint":false},{"year":2016,"finding":"SLC6A3 expression in clear cell renal cell carcinoma (ccRCC) is functionally active for dopamine uptake (demonstrated by [3H]-dopamine uptake assay) and is regulated primarily by HIF-2α (not HIF-1α); siRNA knockdown of HIF-2α in ccRCC cells reduces SLC6A3 expression, and hypoxia can induce SLC6A3 expression in non-malignant renal cells.","method":"[3H]-dopamine uptake assay, siRNA knockdown of HIF-1α and HIF-2α, hypoxia treatment, mRNA expression analysis","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional transport assay combined with siRNA epistasis, single lab, two orthogonal approaches","pmids":["27663598"],"is_preprint":false},{"year":2006,"finding":"Human blood platelets express functional dopamine transporter DAT protein identical to the neuronal form, with pharmacological properties and immunoreactivity consistent with neuronal DAT, demonstrating DAT expression and function in a non-neuronal peripheral cell type.","method":"Pharmacological characterization, immunological detection, microarray/PCR expression analysis in isolated blood platelets","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — multiple orthogonal methods (pharmacology, immunology, expression), single lab","pmids":["16490314"],"is_preprint":false},{"year":2019,"finding":"Potassium channel proteins Kv7.2/7.3 form immunoprecipitable complexes with DAT (and GLT-1) and co-cluster along axonal tracts; presence of Kv7.3 mildly stimulates DAT-mediated uptake in an XE-991 (Kv7 blocker)-reversible manner, and the channel reverses the depolarizing effect induced by DAT substrate, suggesting Kv7.2/7.3 functionally interacts with DAT to readjust membrane potential during dopamine transport.","method":"BioID proximity labeling, co-immunoprecipitation in HEK293 cells, co-transfection in primary neurons with imaging, radioactive substrate uptake assays, electrophysiology","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus functional uptake and electrophysiology, single lab, multiple orthogonal methods","pmids":["30885609"],"is_preprint":false},{"year":2018,"finding":"In DAT Val559 knock-in mice (carrying the autism/ADHD-associated A559V variant), loss of cocaine-induced locomotor activation is driven by SERT blockade and augmented 5-HT2C receptor signaling acting independently of striatal DA release; genetic elimination of high-affinity cocaine-SERT interactions or pharmacological 5-HT2C receptor inhibition restores cocaine-induced locomotion without restoring cocaine-induced DA elevation.","method":"Knock-in mouse model, pharmacological interventions (fluoxetine, 5-HT2C inhibitors, DAT-selective cocaine analog RTI-113), locomotor assays, extracellular DA microdialysis","journal":"Neuropsychopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological epistasis in knock-in mice with multiple behavioral and neurochemical readouts, single lab","pmids":["30578419"],"is_preprint":false},{"year":2014,"finding":"Functional DAT protein is present in stallion sperm and mediates dopamine uptake (demonstrated using the fluorescent substrate ASP+); dopamine applied in vitro decreases sperm motility and acrosomal integrity through DAT, as both effects are reversed by the selective DAT inhibitor vanoxerine (GBR12909) and non-selective inhibitors nomifensine and bupropion.","method":"Immunodetection, fluorescent ASP+ uptake assay, pharmacological inhibition with selective DAT blockers, sperm motility and acrosome integrity assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional transport assay plus pharmacological reversal with selective inhibitors, single lab","pmids":["25402186"],"is_preprint":false},{"year":2006,"finding":"Eight haplotypes in the 5' region of SLC6A3 identified by 22 SNPs show balancing selection and differ in transcriptional activity when transfected in rat dopamine-producing cells; diplotypes of these clades associate with Parkinson's disease risk, with a significant interaction with occupational pesticide exposure in men.","method":"Haplotype transfection into dopaminergic cells for transcriptional activity, population genetics (Tajima's D), case-control association with gene-environment interaction analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional transcriptional assay in dopaminergic cells plus population genetics, single lab","pmids":["16963468"],"is_preprint":false},{"year":2015,"finding":"Increased nigral SLC6A3 mRNA expression (higher DAT activity) is a risk factor for schizophrenia; in vitro promoter-reporter assays confirmed that the protective T allele of rs1478435 attenuates SLC6A3 promoter activity, providing a functional mechanism linking this SNP to altered DAT expression in dopamine neurons.","method":"Postmortem qPCR in isolated nigral DA neurons, in vitro promoter-reporter functional assay, case-control genetic association","journal":"Schizophrenia bulletin","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter functional assay combined with postmortem expression data, single lab, two orthogonal approaches","pmids":["26707863"],"is_preprint":false},{"year":2019,"finding":"Misfolded DAT mutants are retained in the endoplasmic reticulum; atypical DAT inhibitors and partial releasers act as pharmacochaperones by binding folding intermediates and scaffolding them to a folded state that is exported from the ER and delivered to the cell surface, linking atypical inhibitor binding mode to anti-addictive and chaperone functions.","method":"Pharmacological chaperoning experiments with atypical DAT inhibitors; ER retention/surface expression assays (described mechanistically in review of experimental literature)","journal":"Biochemical Society transactions","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mechanistic synthesis citing prior experimental work; this abstract itself does not present primary experimental data, making the evidence level limited","pmids":["31064865"],"is_preprint":false}],"current_model":"SLC6A3/DAT is a plasma membrane dopamine reuptake transporter whose activity is dynamically regulated by N-terminal phosphorylation through PKC, PI3K, and MEK1/2 cascades; its surface trafficking is controlled by PKCβ and is modulated by the GDNF/Ret/Vav2 signaling axis; it forms functional complexes with D2 receptors (regulating surface expression and dopamine neurotoxicity) and Kv7.2/7.3 potassium channels (coupling transport to membrane potential); disease-associated coding variants (e.g., A559V/T356M) disrupt normal PKCβ-regulated trafficking and confer anomalous dopamine efflux; and the 3'-UTR VNTR and 5' promoter haplotypes regulate DAT transcription, influencing in vivo striatal dopamine homeostasis."},"narrative":{"mechanistic_narrative":"SLC6A3 (DAT) is the plasma membrane dopamine reuptake transporter, and its transport activity and surface availability are dynamically governed by N-terminal phosphorylation: site-directed mutagenesis maps PKC (S7), PI3K (T62, S581, T612), and MEK1/2 (S12, T595) phosphoacceptor residues that control surface expression and dopamine uptake Vmax [PMID:12660249]. Beyond reuptake, DAT can run in reverse — activation of Gq-coupled receptors drives PKC-dependent DAT-mediated dopamine efflux [PMID:20477913]. Surface trafficking is further shaped by the GDNF/Ret signaling axis, in which the Rho-family GEF Vav2 is required to regulate DAT surface expression and transport selectively in nucleus accumbens dopamine terminals [PMID:26147533]. DAT operates within physical complexes: it associates with D2 receptors, whose interaction controls DAT surface expression and protects dopaminergic neurons from dopamine neurotoxicity [PMID:28579325], and with Kv7.2/7.3 potassium channels, which co-cluster with DAT and readjust membrane potential during transport [PMID:30885609]. The autism/ADHD-associated coding variant A559V is hyper-phosphorylated, displays constitutively elevated PKCβ activity, resists amphetamine-induced trafficking, and supports anomalous dopamine efflux that is reversed by PKCβ inhibition or N-terminal serine substitution [PMID:25313507]; in knock-in mice this variant remodels cocaine responses through SERT and 5-HT2C receptor signaling [PMID:30578419]. At the transcriptional level, the 3'-UTR VNTR acts as an enhancer in dopamine neurons [PMID:11739616], and 5' promoter haplotypes/SNPs modulate DAT expression with associations to Parkinson's disease and schizophrenia risk [PMID:16963468, PMID:26707863]. DAT is also expressed and transport-active outside the nervous system, including renal carcinoma cells under HIF-2α control [PMID:27663598], blood platelets [PMID:16490314], and sperm [PMID:25402186].","teleology":[{"year":2001,"claim":"Established that non-coding regulatory architecture of SLC6A3 controls its transcription in the relevant cell type, framing DAT level as a genetically tunable variable in dopamine neurons.","evidence":"Reporter assays of the 3'-UTR 9-repeat VNTR via lipid and biolistic transfection in dopaminergic cell lines and primary midbrain neurons","pmids":["11739616"],"confidence":"Medium","gaps":["Does not identify the trans-acting factors binding the VNTR","Enhancer activity in immortalized/primary cells may not reflect in vivo expression magnitude"]},{"year":2003,"claim":"Resolved how DAT activity is post-translationally controlled by mapping distinct N-terminal phosphoacceptor sites to specific kinase cascades, defining the molecular substrate for activity regulation.","evidence":"Mutagenesis of 20 N-terminal sites with kinase inhibitors/activators, dopamine uptake assays, and 32P-labeling","pmids":["12660249"],"confidence":"High","gaps":["Performed in heterologous expression, not native dopamine terminals","Does not establish the trafficking machinery downstream of phosphorylation"]},{"year":2010,"claim":"Showed DAT can function in reverse, linking Gq/PKC signaling to dopamine efflux and establishing the transporter as a bidirectional, signal-regulated conduit.","evidence":"Amperometry in rat substantia nigra slices and HPLC in cells with Gq-receptor and PKC pharmacology","pmids":["20477913"],"confidence":"High","gaps":["Does not identify which N-terminal PKC site mediates efflux in this context","Physiological trigger for endogenous Gq-driven efflux unclear"]},{"year":2015,"claim":"Placed DAT surface regulation within an in vivo GDNF/Ret/Vav2 signaling pathway with regional specificity, connecting extracellular trophic signaling to transporter availability and behavior.","evidence":"Vav2-/- and Ret-/- knockout mice with DAT surface assays, dopamine measurements, and cocaine behavior","pmids":["26147533"],"confidence":"High","gaps":["Molecular link between Vav2 GEF activity and DAT trafficking not resolved","Restricted to nucleus accumbens terminals; striatal generality untested"]},{"year":2017,"claim":"Demonstrated that the D2R–DAT physical complex regulates DAT surface expression and modulates dopamine neurotoxicity, defining a receptor-transporter functional unit.","evidence":"Interfering peptide (DAT-S1) disruption with surface expression, caspase-3/PARP-1 cleavage, and neurotoxicity assays","pmids":["28579325"],"confidence":"Medium","gaps":["Interface residues mediating the complex not mapped","Neuroprotection shown in model system, not in vivo disease context"]},{"year":2019,"claim":"Identified Kv7.2/7.3 channels as DAT partners that couple transport-associated depolarization to membrane potential recovery, linking electrogenic transport to channel activity.","evidence":"BioID, reciprocal Co-IP in HEK293, co-transfection imaging in neurons, uptake assays, and electrophysiology","pmids":["30885609"],"confidence":"Medium","gaps":["Stoichiometry and direct interface of the DAT–Kv7 complex unknown","In vivo functional consequence of the coupling untested"]},{"year":2014,"claim":"Connected a disease coding variant (A559V) to dysregulated PKCβ-dependent trafficking and anomalous efflux, providing a mechanistic basis for transporter dysfunction in neuropsychiatric disease.","evidence":"Surface biotinylation/trafficking, PKCβ activity assays, N-terminal serine mutagenesis, and efflux measurements in transfected cells","pmids":["25313507"],"confidence":"High","gaps":["Mechanism by which A559V constitutively activates PKCβ unresolved","Heterologous-cell findings require native-neuron confirmation"]},{"year":2018,"claim":"Revealed that the A559V variant remodels psychostimulant responses through SERT and 5-HT2C signaling independent of striatal DA release, broadening the circuit-level consequences of a DAT variant.","evidence":"DAT Val559 knock-in mice with fluoxetine/5-HT2C/RTI-113 pharmacology, locomotor assays, and DA microdialysis","pmids":["30578419"],"confidence":"Medium","gaps":["How a DAT variant engages serotonergic signaling mechanistically is unexplained","Single knock-in line, single lab"]},{"year":2006,"claim":"Functional promoter haplotype variation under balancing selection was linked to DAT transcriptional activity and Parkinson's disease risk with gene-environment interaction, extending regulatory control to disease susceptibility.","evidence":"Haplotype reporter transfection in dopaminergic cells, population genetics, and case-control gene-environment association","pmids":["16963468"],"confidence":"Medium","gaps":["Causal SNP within haplotype clades not isolated","Association does not establish DAT level as the disease driver"]},{"year":2015,"claim":"Linked elevated nigral DAT mRNA to schizophrenia risk and provided a functional promoter SNP (rs1478435) mechanism, reinforcing transcriptional dosage as a disease-relevant axis.","evidence":"Postmortem qPCR in nigral DA neurons, promoter-reporter assay, and case-control association","pmids":["26707863"],"confidence":"Medium","gaps":["Direction of causality between DAT expression and disease unproven","Other promoter elements not surveyed"]},{"year":2016,"claim":"Showed DAT is functionally expressed outside the nervous system and is transcriptionally controlled by HIF-2α in renal carcinoma, indicating a hypoxia-regulated context for transporter expression.","evidence":"[3H]-dopamine uptake, HIF-1α/HIF-2α siRNA knockdown, and hypoxia treatment in ccRCC cells","pmids":["27663598"],"confidence":"Medium","gaps":["Biological role of dopamine uptake in renal cancer unclear","Direct vs indirect HIF-2α regulation of SLC6A3 not distinguished"]},{"year":2019,"claim":"Proposed that atypical DAT inhibitors act as pharmacochaperones rescuing ER-retained misfolded DAT to the surface, linking inhibitor binding mode to folding correction.","evidence":"Mechanistic synthesis of pharmacochaperoning and ER retention/surface expression experiments (review)","pmids":["31064865"],"confidence":"Low","gaps":["Review without primary data in this entry","Structural basis of chaperone binding to folding intermediates not directly demonstrated here"]},{"year":null,"claim":"How phosphorylation, trophic signaling, and the D2R/Kv7 complexes are integrated to set DAT surface density and direction of transport in native dopamine terminals remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural/biochemical model linking N-terminal phosphosites to specific trafficking machinery","Interfaces of DAT physical complexes not mapped","In vivo causal contribution of transcriptional variants to disease unestablished"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[1,2,6,7,10]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[1,6]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,3,4,5,8]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[13]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[1,2]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[1,6]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,4,5]}],"complexes":["D2R–DAT complex","DAT–Kv7.2/7.3 complex"],"partners":["DRD2","KCNQ2","KCNQ3","VAV2","RET"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q01959","full_name":"Sodium-dependent dopamine transporter","aliases":["Solute carrier family 6 member 3"],"length_aa":620,"mass_kda":68.5,"function":"Mediates sodium- and chloride-dependent transport of dopamine (PubMed:10375632, PubMed:11093780, PubMed:1406597, PubMed:15505207, PubMed:19478460, PubMed:39112701, PubMed:39112703, PubMed:39112705, PubMed:8302271). Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline) (By similarity). Regulator of light-dependent retinal hyaloid vessel regression, downstream of OPN5 signaling (By similarity)","subcellular_location":"Cell membrane; Cell projection, neuron projection; Cell projection, axon","url":"https://www.uniprot.org/uniprotkb/Q01959/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SLC6A3","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SLC6A3","total_profiled":1310},"omim":[{"mim_id":"616417","title":"ADHESION G PROTEIN-COUPLED RECEPTOR L3; ADGRL3","url":"https://www.omim.org/entry/616417"},{"mim_id":"614613","title":"ACRODYSOSTOSIS 2 WITH OR WITHOUT HORMONE RESISTANCE; ACRDYS2","url":"https://www.omim.org/entry/614613"},{"mim_id":"613637","title":"TUBERCULIN SKIN TEST REACTIVITY QUANTITATIVE TRAIT LOCUS","url":"https://www.omim.org/entry/613637"},{"mim_id":"613135","title":"PARKINSONISM-DYSTONIA 1, INFANTILE-ONSET; PKDYS1","url":"https://www.omim.org/entry/613135"},{"mim_id":"612276","title":"YRDC DOMAIN-CONTAINING PROTEIN; YRDC","url":"https://www.omim.org/entry/612276"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"brain","ntpm":92.9}],"url":"https://www.proteinatlas.org/search/SLC6A3"},"hgnc":{"alias_symbol":["DAT"],"prev_symbol":["DAT1"]},"alphafold":{"accession":"Q01959","domains":[{"cath_id":"1.20.1740.10","chopping":"67-185_211-575","consensus_level":"high","plddt":93.7139,"start":67,"end":575},{"cath_id":"-","chopping":"584-620","consensus_level":"medium","plddt":91.5873,"start":584,"end":620}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01959","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q01959-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q01959-F1-predicted_aligned_error_v6.png","plddt_mean":86.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SLC6A3","jax_strain_url":"https://www.jax.org/strain/search?query=SLC6A3"},"sequence":{"accession":"Q01959","fasta_url":"https://rest.uniprot.org/uniprotkb/Q01959.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q01959/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01959"}},"corpus_meta":[{"pmid":"20019219","id":"PMC_20019219","title":"The role of DAT-SPECT in movement disorders.","date":"2010","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/20019219","citation_count":230,"is_preprint":false},{"pmid":"15872345","id":"PMC_15872345","title":"Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene.","date":"2005","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15872345","citation_count":221,"is_preprint":false},{"pmid":"11739616","id":"PMC_11739616","title":"The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons.","date":"2001","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11739616","citation_count":165,"is_preprint":false},{"pmid":"17525955","id":"PMC_17525955","title":"Analysis of DRD4 and DAT polymorphisms and behavioral inhibition in healthy adults: implications for impulsivity.","date":"2008","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17525955","citation_count":164,"is_preprint":false},{"pmid":"17486648","id":"PMC_17486648","title":"Role of DAT-SPECT in the diagnostic work up of parkinsonism.","date":"2007","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/17486648","citation_count":156,"is_preprint":false},{"pmid":"19890261","id":"PMC_19890261","title":"Multicenter analysis of the SLC6A3/DAT1 VNTR haplotype in persistent ADHD suggests differential involvement of the gene in childhood and persistent ADHD.","date":"2009","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19890261","citation_count":147,"is_preprint":false},{"pmid":"19844206","id":"PMC_19844206","title":"Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans.","date":"2009","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/19844206","citation_count":136,"is_preprint":false},{"pmid":"19091889","id":"PMC_19091889","title":"Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3.","date":"2008","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19091889","citation_count":120,"is_preprint":false},{"pmid":"25313507","id":"PMC_25313507","title":"SLC6A3 coding variant Ala559Val found in two autism probands alters dopamine transporter function and trafficking.","date":"2014","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/25313507","citation_count":102,"is_preprint":false},{"pmid":"34650206","id":"PMC_34650206","title":"The dopamine transporter gene SLC6A3: multidisease risks.","date":"2021","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/34650206","citation_count":84,"is_preprint":false},{"pmid":"14531043","id":"PMC_14531043","title":"DAT imaging in drug-induced and psychogenic parkinsonism.","date":"2003","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/14531043","citation_count":78,"is_preprint":false},{"pmid":"31303260","id":"PMC_31303260","title":"Which Dopamine Polymorphisms Are Functional? Systematic Review and Meta-analysis of COMT, DAT, DBH, DDC, DRD1-5, MAOA, MAOB, TH, VMAT1, and VMAT2.","date":"2019","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/31303260","citation_count":71,"is_preprint":false},{"pmid":"18802924","id":"PMC_18802924","title":"Association of the dopamine transporter (SLC6A3/DAT1) gene 9-6 haplotype with adult ADHD.","date":"2008","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18802924","citation_count":69,"is_preprint":false},{"pmid":"12660249","id":"PMC_12660249","title":"Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12660249","citation_count":67,"is_preprint":false},{"pmid":"9790747","id":"PMC_9790747","title":"Population studies of polymorphisms at loci of neuropsychiatric interest (tryptophan hydroxylase (TPH), dopamine transporter protein (SLC6A3), D3 dopamine receptor (DRD3), apolipoprotein E (APOE), mu opioid receptor (OPRM1), and ciliary neurotrophic factor (CNTF)).","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9790747","citation_count":63,"is_preprint":false},{"pmid":"21404331","id":"PMC_21404331","title":"Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human single photon emission computed tomography studies.","date":"2011","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21404331","citation_count":60,"is_preprint":false},{"pmid":"26831905","id":"PMC_26831905","title":"Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma.","date":"2016","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26831905","citation_count":56,"is_preprint":false},{"pmid":"24633632","id":"PMC_24633632","title":"Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.","date":"2014","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/24633632","citation_count":54,"is_preprint":false},{"pmid":"9703021","id":"PMC_9703021","title":"Molecular and biochemical characterization of the aaNAT1 (Dat) locus in Drosophila melanogaster: differential expression of two gene products.","date":"1998","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9703021","citation_count":54,"is_preprint":false},{"pmid":"22551036","id":"PMC_22551036","title":"Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.","date":"2012","source":"Alcoholism, clinical and experimental research","url":"https://pubmed.ncbi.nlm.nih.gov/22551036","citation_count":53,"is_preprint":false},{"pmid":"14755448","id":"PMC_14755448","title":"Clinical features of psychotic disorders and polymorphisms in HT2A, DRD2, DRD4, SLC6A3 (DAT1), and BDNF: a family based association study.","date":"2004","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14755448","citation_count":52,"is_preprint":false},{"pmid":"21826203","id":"PMC_21826203","title":"Genotype and ancestry modulate brain's DAT availability in healthy humans.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21826203","citation_count":51,"is_preprint":false},{"pmid":"17171650","id":"PMC_17171650","title":"Dopaminergic polymorphisms in Tourette syndrome: association with the DAT gene (SLC6A3).","date":"2007","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17171650","citation_count":51,"is_preprint":false},{"pmid":"23340505","id":"PMC_23340505","title":"Dopamine transporter DAT and receptor DRD2 variants affect risk of lethal cocaine abuse: a gene-gene-environment interaction.","date":"2013","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/23340505","citation_count":50,"is_preprint":false},{"pmid":"16526040","id":"PMC_16526040","title":"The effect of dopamine D2, D5 receptor and transporter (SLC6A3) polymorphisms on the cue-elicited heroin craving in Chinese.","date":"2006","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16526040","citation_count":45,"is_preprint":false},{"pmid":"19676101","id":"PMC_19676101","title":"Effect of dopamine transporter gene (SLC6A3) variation on dorsal anterior cingulate function in attention-deficit/hyperactivity disorder.","date":"2010","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19676101","citation_count":45,"is_preprint":false},{"pmid":"19450132","id":"PMC_19450132","title":"Polymorphisms in the dopamine transporter gene (SLC6A3/DAT1) and alcohol dependence in humans: a systematic review.","date":"2009","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/19450132","citation_count":42,"is_preprint":false},{"pmid":"30472113","id":"PMC_30472113","title":"Behavioral characterization of DAT-KO rats and evidence of asocial-like phenotypes in DAT-HET rats: The potential involvement of norepinephrine system.","date":"2018","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/30472113","citation_count":42,"is_preprint":false},{"pmid":"19590515","id":"PMC_19590515","title":"Association between dopaminergic genes (SLC6A3 and DRD2) and stuttering among Han Chinese.","date":"2009","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19590515","citation_count":41,"is_preprint":false},{"pmid":"32102440","id":"PMC_32102440","title":"Antiparkinson Drug Benztropine Suppresses Tumor Growth, Circulating Tumor Cells, and Metastasis by Acting on SLC6A3/DAT and Reducing STAT3.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32102440","citation_count":41,"is_preprint":false},{"pmid":"16963468","id":"PMC_16963468","title":"5' and 3' region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study.","date":"2006","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16963468","citation_count":39,"is_preprint":false},{"pmid":"23417514","id":"PMC_23417514","title":"An evaluation of the serotonin system and perseverative, compulsive, stereotypical, and hyperactive behaviors in dopamine transporter (DAT) knockout mice.","date":"2013","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23417514","citation_count":38,"is_preprint":false},{"pmid":"35672374","id":"PMC_35672374","title":"DAT and TH expression marks human Parkinson's disease in peripheral immune cells.","date":"2022","source":"NPJ Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/35672374","citation_count":37,"is_preprint":false},{"pmid":"19766158","id":"PMC_19766158","title":"Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study.","date":"2009","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/19766158","citation_count":37,"is_preprint":false},{"pmid":"28679601","id":"PMC_28679601","title":"Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease.","date":"2017","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28679601","citation_count":37,"is_preprint":false},{"pmid":"18361424","id":"PMC_18361424","title":"Family based association study of pediatric bipolar disorder and the dopamine transporter gene (SLC6A3).","date":"2008","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18361424","citation_count":37,"is_preprint":false},{"pmid":"26147533","id":"PMC_26147533","title":"Identification of a Vav2-dependent mechanism for GDNF/Ret control of mesolimbic DAT trafficking.","date":"2015","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26147533","citation_count":37,"is_preprint":false},{"pmid":"21554332","id":"PMC_21554332","title":"The association between the SLC6A3 VNTR 9-repeat allele and alcoholism-a meta-analysis.","date":"2011","source":"Alcoholism, clinical and experimental research","url":"https://pubmed.ncbi.nlm.nih.gov/21554332","citation_count":36,"is_preprint":false},{"pmid":"24211691","id":"PMC_24211691","title":"SLC6A3 is a risk factor for Parkinson's disease: a meta-analysis of sixteen years' studies.","date":"2013","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/24211691","citation_count":35,"is_preprint":false},{"pmid":"16490314","id":"PMC_16490314","title":"Characterization of the neuronal dopamine transporter DAT in human blood platelets.","date":"2006","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/16490314","citation_count":34,"is_preprint":false},{"pmid":"29375406","id":"PMC_29375406","title":"DNA Methylation at the DAT Promoter and Risk for Psychopathology: Intergenerational Transmission between School-Age Youths and Their Parents in a Community Sample.","date":"2018","source":"Frontiers in psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/29375406","citation_count":34,"is_preprint":false},{"pmid":"204332","id":"PMC_204332","title":"Circular dichroism studies of the interaction of a limited hydrolysate of T4 gene 32 protein with T4 DNA and poly[d(A-T)].poly[d(A-T)].","date":"1978","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/204332","citation_count":34,"is_preprint":false},{"pmid":"21354244","id":"PMC_21354244","title":"The role of dopamine transporter (SLC6A3) and dopamine D2 receptor/ankyrin repeat and kinase domain containing 1 (DRD2/ANKK1) gene polymorphisms in personality traits.","date":"2011","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21354244","citation_count":33,"is_preprint":false},{"pmid":"26058807","id":"PMC_26058807","title":"A 40-bp VNTR polymorphism in the 3'-untranslated region of DAT1/SLC6A3 is associated with ADHD but not with alcoholism.","date":"2015","source":"Behavioral and brain functions : BBF","url":"https://pubmed.ncbi.nlm.nih.gov/26058807","citation_count":33,"is_preprint":false},{"pmid":"16861140","id":"PMC_16861140","title":"Striatal dopamine transporter availability and DAT-1 gene in adults with ADHD: no higher DAT availability in patients with homozygosity for the 10-repeat allele.","date":"2006","source":"The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/16861140","citation_count":33,"is_preprint":false},{"pmid":"20554017","id":"PMC_20554017","title":"PTSD and dopaminergic genes, DRD2 and DAT, in multigenerational families exposed to the Spitak earthquake.","date":"2010","source":"Psychiatry research","url":"https://pubmed.ncbi.nlm.nih.gov/20554017","citation_count":32,"is_preprint":false},{"pmid":"26686514","id":"PMC_26686514","title":"DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.","date":"2015","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/26686514","citation_count":31,"is_preprint":false},{"pmid":"27663598","id":"PMC_27663598","title":"Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27663598","citation_count":29,"is_preprint":false},{"pmid":"32035946","id":"PMC_32035946","title":"Unraveling correlative roles of dopamine transporter (DAT) and Parkin in Parkinson's disease (PD) - A road to discovery?","date":"2020","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/32035946","citation_count":29,"is_preprint":false},{"pmid":"33558587","id":"PMC_33558587","title":"Sex-dependent alterations in behavior, drug responses and dopamine transporter expression in heterozygous DAT-Cre mice.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33558587","citation_count":28,"is_preprint":false},{"pmid":"25212851","id":"PMC_25212851","title":"Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease.","date":"2014","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25212851","citation_count":28,"is_preprint":false},{"pmid":"19309018","id":"PMC_19309018","title":"Genetic polymorphisms in the DRD2, DRD3, and SLC6A3 gene in elderly patients with delirium.","date":"2010","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19309018","citation_count":26,"is_preprint":false},{"pmid":"28406934","id":"PMC_28406934","title":"DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28406934","citation_count":26,"is_preprint":false},{"pmid":"23911780","id":"PMC_23911780","title":"DAT genotype modulates striatal processing and long-term memory for items associated with reward and punishment.","date":"2013","source":"Neuropsychologia","url":"https://pubmed.ncbi.nlm.nih.gov/23911780","citation_count":26,"is_preprint":false},{"pmid":"23912772","id":"PMC_23912772","title":"Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice.","date":"2013","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23912772","citation_count":25,"is_preprint":false},{"pmid":"20085672","id":"PMC_20085672","title":"Social withdrawal and gambling-like profile after lentiviral manipulation of DAT expression in the rat accumbens.","date":"2010","source":"The international journal of neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20085672","citation_count":25,"is_preprint":false},{"pmid":"8825631","id":"PMC_8825631","title":"The dopamine transporter protein gene (SLC6A3): primary linkage mapping and linkage studies in Tourette syndrome.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8825631","citation_count":24,"is_preprint":false},{"pmid":"20477913","id":"PMC_20477913","title":"PKC links Gq-coupled receptors to DAT-mediated dopamine release.","date":"2010","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20477913","citation_count":24,"is_preprint":false},{"pmid":"23036843","id":"PMC_23036843","title":"High frequency electro-acupuncture enhances striatum DAT and D1 receptor expression, but decreases D2 receptor level in 6-OHDA lesioned rats.","date":"2012","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/23036843","citation_count":24,"is_preprint":false},{"pmid":"32680528","id":"PMC_32680528","title":"Slc6a3-dependent expression of a CAPS-associated Nlrp3 allele results in progressive behavioral abnormalities and neuroinflammation in aging mice.","date":"2020","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32680528","citation_count":23,"is_preprint":false},{"pmid":"21050355","id":"PMC_21050355","title":"Relationship between premature ejaculation and genetic polymorphisms of the dopamine transporter gene (SLC6A3).","date":"2010","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/21050355","citation_count":23,"is_preprint":false},{"pmid":"31064865","id":"PMC_31064865","title":"How to rescue misfolded SERT, DAT and NET: targeting conformational intermediates with atypical inhibitors and partial releasers.","date":"2019","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/31064865","citation_count":22,"is_preprint":false},{"pmid":"33979604","id":"PMC_33979604","title":"Generation of a DAT-P2A-Flpo mouse line for intersectional genetic targeting of dopamine neuron subpopulations.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33979604","citation_count":21,"is_preprint":false},{"pmid":"25402186","id":"PMC_25402186","title":"Presence and function of dopamine transporter (DAT) in stallion sperm: dopamine modulates sperm motility and acrosomal integrity.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25402186","citation_count":21,"is_preprint":false},{"pmid":"21595008","id":"PMC_21595008","title":"Exploring DRD4 and its interaction with SLC6A3 as possible risk factors for adult ADHD: a meta-analysis in four European populations.","date":"2011","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21595008","citation_count":20,"is_preprint":false},{"pmid":"10898909","id":"PMC_10898909","title":"Investigation of dopamine receptor (DRD4) and dopamine transporter (DAT) polymorphisms for genetic linkage or association to panic disorder.","date":"2000","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10898909","citation_count":20,"is_preprint":false},{"pmid":"30353564","id":"PMC_30353564","title":"The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease.","date":"2018","source":"The Journal of pharmacy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30353564","citation_count":19,"is_preprint":false},{"pmid":"15091313","id":"PMC_15091313","title":"DAT polymorphism and diverse clinical manifestations in methamphetamine abusers.","date":"2004","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15091313","citation_count":19,"is_preprint":false},{"pmid":"22698582","id":"PMC_22698582","title":"DRD2/ANKK1 TaqIA and SLC6A3 VNTR polymorphisms in alcohol dependence: association and gene-gene interaction study in a population of Central Italy.","date":"2012","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/22698582","citation_count":18,"is_preprint":false},{"pmid":"25684044","id":"PMC_25684044","title":"Association study of the SLC6A3 VNTR (DAT) and DRD2/ANKK1 Taq1A polymorphisms with alcohol dependence in a population from northeastern Brazil.","date":"2015","source":"Alcoholism, clinical and experimental research","url":"https://pubmed.ncbi.nlm.nih.gov/25684044","citation_count":18,"is_preprint":false},{"pmid":"26350252","id":"PMC_26350252","title":"DRD4 and SLC6A3 gene polymorphisms are associated with food intake and nutritional status in children in early stages of development.","date":"2015","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26350252","citation_count":17,"is_preprint":false},{"pmid":"19761593","id":"PMC_19761593","title":"Influences of polymorphic variants of DRD2 and SLC6A3 genes, and their combinations on smoking in Polish population.","date":"2009","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19761593","citation_count":17,"is_preprint":false},{"pmid":"30784211","id":"PMC_30784211","title":"Comparative analysis of the influence of a high-fat/high-carbohydrate diet on the level of anxiety and neuromotor and cognitive functions in Wistar and DAT-KO rats.","date":"2019","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/30784211","citation_count":17,"is_preprint":false},{"pmid":"30578419","id":"PMC_30578419","title":"Serotonin transporter inhibition and 5-HT2C receptor activation drive loss of cocaine-induced locomotor activation in DAT Val559 mice.","date":"2018","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30578419","citation_count":17,"is_preprint":false},{"pmid":"30316985","id":"PMC_30316985","title":"DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease.","date":"2018","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/30316985","citation_count":16,"is_preprint":false},{"pmid":"32277231","id":"PMC_32277231","title":"The SLC6A3 gene polymorphism is related to the development of attentional functions but not to ADHD.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32277231","citation_count":16,"is_preprint":false},{"pmid":"32415851","id":"PMC_32415851","title":"DNA methylation of the 5'-UTR DAT 1 gene in Parkinson's disease patients.","date":"2020","source":"Acta neurologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/32415851","citation_count":16,"is_preprint":false},{"pmid":"29172706","id":"PMC_29172706","title":"Methylation changes and pathways affected in preterm birth: a role for SLC6A3 in neurodevelopment.","date":"2017","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/29172706","citation_count":16,"is_preprint":false},{"pmid":"26593110","id":"PMC_26593110","title":"Meta-analysis of the association of the SLC6A3 3'-UTR VNTR with cognition.","date":"2015","source":"Neuroscience and biobehavioral reviews","url":"https://pubmed.ncbi.nlm.nih.gov/26593110","citation_count":15,"is_preprint":false},{"pmid":"25642918","id":"PMC_25642918","title":"TPH, SLC6A2, SLC6A3, DRD2 and DRD4 Polymorphisms and Neuroendocrine Factors Predict SSRIs Treatment Outcome in the Chinese Population with Major Depression.","date":"2015","source":"Pharmacopsychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/25642918","citation_count":15,"is_preprint":false},{"pmid":"32171819","id":"PMC_32171819","title":"Motor Transitions' Peculiarity of Heterozygous DAT Rats When Offspring of an Unconventional KOxWT Mating.","date":"2020","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32171819","citation_count":15,"is_preprint":false},{"pmid":"21308469","id":"PMC_21308469","title":"Functional analysis of the DAT gene promoter using transient Catharanthus roseus and stable Nicotiana tabacum transformation systems.","date":"2011","source":"Plant cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/21308469","citation_count":14,"is_preprint":false},{"pmid":"25656223","id":"PMC_25656223","title":"An association between a dopamine transporter gene (SLC6A3) haplotype and ADHD symptom measures in nonclinical adults.","date":"2015","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25656223","citation_count":14,"is_preprint":false},{"pmid":"33887543","id":"PMC_33887543","title":"SLC6A3 as a potential circulating biomarker for gastric cancer detection and progression monitoring.","date":"2021","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/33887543","citation_count":13,"is_preprint":false},{"pmid":"30186226","id":"PMC_30186226","title":"SLC6A3 Polymorphism Predisposes to Dopamine Overdose in Parkinson's Disease.","date":"2018","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30186226","citation_count":13,"is_preprint":false},{"pmid":"34357147","id":"PMC_34357147","title":"Parkinson's Disease: Personalized Pathway of Care for Device-Aided Therapies (DAT) and the Role of Continuous Objective Monitoring (COM) Using Wearable Sensors.","date":"2021","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34357147","citation_count":13,"is_preprint":false},{"pmid":"18774292","id":"PMC_18774292","title":"Dual DAT/sigma1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol.","date":"2008","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/18774292","citation_count":13,"is_preprint":false},{"pmid":"30697146","id":"PMC_30697146","title":"Increased Vesicular Monoamine Transporter 2 (VMAT2) and Dopamine Transporter (DAT) Expression in Adolescent Brain Development: A Longitudinal Micro-PET/CT Study in Rodent.","date":"2019","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30697146","citation_count":13,"is_preprint":false},{"pmid":"35401884","id":"PMC_35401884","title":"Screening and Validation of a Carvacrol-Targeting Viability-Regulating Protein, SLC6A3, in Liver Hepatocellular Carcinoma.","date":"2022","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/35401884","citation_count":12,"is_preprint":false},{"pmid":"33935841","id":"PMC_33935841","title":"Autism-Associated Variant in the SLC6A3 Gene Alters the Oral Microbiome and Metabolism in a Murine Model.","date":"2021","source":"Frontiers in psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/33935841","citation_count":12,"is_preprint":false},{"pmid":"28579325","id":"PMC_28579325","title":"A peptide disrupting the D2R-DAT interaction protects against dopamine neurotoxicity.","date":"2017","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28579325","citation_count":12,"is_preprint":false},{"pmid":"26707863","id":"PMC_26707863","title":"Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean Cohorts.","date":"2015","source":"Schizophrenia bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/26707863","citation_count":12,"is_preprint":false},{"pmid":"26364979","id":"PMC_26364979","title":"Living without DAT: Loss and compensation of the dopamine transporter gene in sauropsids (birds and reptiles).","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26364979","citation_count":12,"is_preprint":false},{"pmid":"30885609","id":"PMC_30885609","title":"Identification of potassium channel proteins Kv7.2/7.3 as common partners of the dopamine and glutamate transporters DAT and GLT-1.","date":"2019","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30885609","citation_count":12,"is_preprint":false},{"pmid":"23628791","id":"PMC_23628791","title":"Down-regulation of LRRK2 in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicity.","date":"2013","source":"Neurotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/23628791","citation_count":12,"is_preprint":false},{"pmid":"37694119","id":"PMC_37694119","title":"Selective dopaminergic vulnerability in Parkinson's disease: new insights into the role of DAT.","date":"2023","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37694119","citation_count":11,"is_preprint":false},{"pmid":"28803562","id":"PMC_28803562","title":"Dopamine receptor D2 (DRD2), dopamine transporter solute carrier family C6, member 4 (SLC6A3), and catechol-O-methyltransferase (COMT) genes as moderators of the relation between maternal history of maltreatment and infant emotion regulation.","date":"2017","source":"Development and psychopathology","url":"https://pubmed.ncbi.nlm.nih.gov/28803562","citation_count":11,"is_preprint":false},{"pmid":"32991141","id":"PMC_32991141","title":"Focus on Human Monoamine Transporter Selectivity. New Human DAT and NET Models, Experimental Validation, and SERT Affinity Exploration.","date":"2020","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32991141","citation_count":11,"is_preprint":false},{"pmid":"31440993","id":"PMC_31440993","title":"A Meta-analysis of the Association Between SLC6A3 Gene Polymorphisms and Schizophrenia.","date":"2019","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/31440993","citation_count":10,"is_preprint":false},{"pmid":"34199792","id":"PMC_34199792","title":"SLC6A3 (DAT1) as a Novel Candidate Biomarker Gene for Suicidal Behavior.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/34199792","citation_count":10,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54168,"output_tokens":3601,"usd":0.108259,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11399,"output_tokens":4066,"usd":0.079323,"stage2_stop_reason":"end_turn"},"total_usd":0.187582,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"The 9-repeat VNTR in the 3' untranslated region of the human DAT gene (SLC6A3) functions as a transcriptional enhancer in dopamine neurons, demonstrated by lipid transfection into an immortalized dopaminergic cell line and biolistic transfection into dopamine neurons in neonatal rat midbrain slices.\",\n      \"method\": \"Lipid transfection and biolistic transfection reporter assays in dopaminergic cell lines and primary dopamine neurons\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal transfection systems (cell line + primary neurons), single lab\",\n      \"pmids\": [\"11739616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"DAT phosphorylation is regulated by PI3K, PKC, and MEK1/2 kinase cascades through phosphoacceptor sites concentrated in the N-terminus of DAT; specific N-terminal serine/threonine residues (S7 for PKC; T62, S581, T612 for PI3K; S12, T595 for MEK1/2) are required for kinase-dependent regulation of DAT surface expression and dopamine uptake Vmax, confirmed by 32P-labeling studies.\",\n      \"method\": \"Site-directed mutagenesis of 20 DAT N-terminal phosphoacceptor sites combined with pharmacological kinase inhibitors/activators, dopamine uptake assays, and 32P-labeling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro mutagenesis at 20 sites combined with biochemical assays and radioisotope labeling, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"12660249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Activation of Gq-coupled receptors (group I metabotropic glutamate receptors in rat substantia nigra slices; muscarinic receptors in DAT-expressing cell line) induces DAT-mediated dopamine efflux (reverse transport) through a PKC-dependent mechanism, as shown by amperometry/HPLC measurements inhibited by DAT antagonists.\",\n      \"method\": \"Amperometry in rat brain slices, HPLC in cell lines, pharmacological activation/inhibition of Gq-coupled receptors and PKC\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — two independent experimental systems (brain slices + cell line), specific pharmacological controls, mechanistically defined PKC link\",\n      \"pmids\": [\"20477913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The autism/ADHD-associated DAT coding variant A559V (hDAT A559V) is hyper-phosphorylated at N-terminal serine residues, is resistant to amphetamine-induced cell surface redistribution (trafficking), exhibits constitutively elevated PKCβ activity, and lacks amphetamine-induced dopamine efflux. Pharmacological inhibition of PKCβ or Ala substitution of the five N-terminal serines restores AMPH-induced trafficking and DA efflux.\",\n      \"method\": \"Cell surface biotinylation/trafficking assays, PKCβ activity assays, N-terminal serine mutagenesis, dopamine efflux measurements in transfected cells\",\n      \"journal\": \"Translational psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis, pharmacological rescue, multiple orthogonal biochemical readouts in single rigorous study\",\n      \"pmids\": [\"25313507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The Rho-family guanine nucleotide exchange factor Vav2 is required for GDNF/Ret-dependent regulation of DAT cell surface expression and transport activity selectively in nucleus accumbens dopamine terminals; Vav2-/- and Ret-/- mice show elevated DAT activity with increased intracellular DA and reduced cocaine behavioral response.\",\n      \"method\": \"Genetic knockout mouse models (Vav2-/-, Ret-/-), DAT surface expression assays, dopamine measurements, behavioral cocaine response\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in two independent KO mouse lines, combined with biochemical and behavioral readouts, demonstrating in vivo pathway position\",\n      \"pmids\": [\"26147533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A peptide (DAT-S1) that disrupts the D2 receptor–DAT protein complex inhibits DAT cell surface expression and protects dopaminergic neurons against dopamine neurotoxicity by inhibiting caspase-3 and PARP-1 cleavage; this demonstrates that the D2R–DAT complex regulates DAT surface expression and thereby dopamine reuptake and intracellular dopamine levels.\",\n      \"method\": \"Interfering peptide disruption of D2R-DAT complex, cell surface expression assay, caspase-3/PARP-1 cleavage assay, neurotoxicity assay\",\n      \"journal\": \"Experimental neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — peptide disruption with multiple downstream biochemical readouts, single lab\",\n      \"pmids\": [\"28579325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SLC6A3 expression in clear cell renal cell carcinoma (ccRCC) is functionally active for dopamine uptake (demonstrated by [3H]-dopamine uptake assay) and is regulated primarily by HIF-2α (not HIF-1α); siRNA knockdown of HIF-2α in ccRCC cells reduces SLC6A3 expression, and hypoxia can induce SLC6A3 expression in non-malignant renal cells.\",\n      \"method\": \"[3H]-dopamine uptake assay, siRNA knockdown of HIF-1α and HIF-2α, hypoxia treatment, mRNA expression analysis\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional transport assay combined with siRNA epistasis, single lab, two orthogonal approaches\",\n      \"pmids\": [\"27663598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Human blood platelets express functional dopamine transporter DAT protein identical to the neuronal form, with pharmacological properties and immunoreactivity consistent with neuronal DAT, demonstrating DAT expression and function in a non-neuronal peripheral cell type.\",\n      \"method\": \"Pharmacological characterization, immunological detection, microarray/PCR expression analysis in isolated blood platelets\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple orthogonal methods (pharmacology, immunology, expression), single lab\",\n      \"pmids\": [\"16490314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Potassium channel proteins Kv7.2/7.3 form immunoprecipitable complexes with DAT (and GLT-1) and co-cluster along axonal tracts; presence of Kv7.3 mildly stimulates DAT-mediated uptake in an XE-991 (Kv7 blocker)-reversible manner, and the channel reverses the depolarizing effect induced by DAT substrate, suggesting Kv7.2/7.3 functionally interacts with DAT to readjust membrane potential during dopamine transport.\",\n      \"method\": \"BioID proximity labeling, co-immunoprecipitation in HEK293 cells, co-transfection in primary neurons with imaging, radioactive substrate uptake assays, electrophysiology\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus functional uptake and electrophysiology, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"30885609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In DAT Val559 knock-in mice (carrying the autism/ADHD-associated A559V variant), loss of cocaine-induced locomotor activation is driven by SERT blockade and augmented 5-HT2C receptor signaling acting independently of striatal DA release; genetic elimination of high-affinity cocaine-SERT interactions or pharmacological 5-HT2C receptor inhibition restores cocaine-induced locomotion without restoring cocaine-induced DA elevation.\",\n      \"method\": \"Knock-in mouse model, pharmacological interventions (fluoxetine, 5-HT2C inhibitors, DAT-selective cocaine analog RTI-113), locomotor assays, extracellular DA microdialysis\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological epistasis in knock-in mice with multiple behavioral and neurochemical readouts, single lab\",\n      \"pmids\": [\"30578419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Functional DAT protein is present in stallion sperm and mediates dopamine uptake (demonstrated using the fluorescent substrate ASP+); dopamine applied in vitro decreases sperm motility and acrosomal integrity through DAT, as both effects are reversed by the selective DAT inhibitor vanoxerine (GBR12909) and non-selective inhibitors nomifensine and bupropion.\",\n      \"method\": \"Immunodetection, fluorescent ASP+ uptake assay, pharmacological inhibition with selective DAT blockers, sperm motility and acrosome integrity assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional transport assay plus pharmacological reversal with selective inhibitors, single lab\",\n      \"pmids\": [\"25402186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Eight haplotypes in the 5' region of SLC6A3 identified by 22 SNPs show balancing selection and differ in transcriptional activity when transfected in rat dopamine-producing cells; diplotypes of these clades associate with Parkinson's disease risk, with a significant interaction with occupational pesticide exposure in men.\",\n      \"method\": \"Haplotype transfection into dopaminergic cells for transcriptional activity, population genetics (Tajima's D), case-control association with gene-environment interaction analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional transcriptional assay in dopaminergic cells plus population genetics, single lab\",\n      \"pmids\": [\"16963468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Increased nigral SLC6A3 mRNA expression (higher DAT activity) is a risk factor for schizophrenia; in vitro promoter-reporter assays confirmed that the protective T allele of rs1478435 attenuates SLC6A3 promoter activity, providing a functional mechanism linking this SNP to altered DAT expression in dopamine neurons.\",\n      \"method\": \"Postmortem qPCR in isolated nigral DA neurons, in vitro promoter-reporter functional assay, case-control genetic association\",\n      \"journal\": \"Schizophrenia bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter functional assay combined with postmortem expression data, single lab, two orthogonal approaches\",\n      \"pmids\": [\"26707863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Misfolded DAT mutants are retained in the endoplasmic reticulum; atypical DAT inhibitors and partial releasers act as pharmacochaperones by binding folding intermediates and scaffolding them to a folded state that is exported from the ER and delivered to the cell surface, linking atypical inhibitor binding mode to anti-addictive and chaperone functions.\",\n      \"method\": \"Pharmacological chaperoning experiments with atypical DAT inhibitors; ER retention/surface expression assays (described mechanistically in review of experimental literature)\",\n      \"journal\": \"Biochemical Society transactions\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mechanistic synthesis citing prior experimental work; this abstract itself does not present primary experimental data, making the evidence level limited\",\n      \"pmids\": [\"31064865\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SLC6A3/DAT is a plasma membrane dopamine reuptake transporter whose activity is dynamically regulated by N-terminal phosphorylation through PKC, PI3K, and MEK1/2 cascades; its surface trafficking is controlled by PKCβ and is modulated by the GDNF/Ret/Vav2 signaling axis; it forms functional complexes with D2 receptors (regulating surface expression and dopamine neurotoxicity) and Kv7.2/7.3 potassium channels (coupling transport to membrane potential); disease-associated coding variants (e.g., A559V/T356M) disrupt normal PKCβ-regulated trafficking and confer anomalous dopamine efflux; and the 3'-UTR VNTR and 5' promoter haplotypes regulate DAT transcription, influencing in vivo striatal dopamine homeostasis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SLC6A3 (DAT) is the plasma membrane dopamine reuptake transporter, and its transport activity and surface availability are dynamically governed by N-terminal phosphorylation: site-directed mutagenesis maps PKC (S7), PI3K (T62, S581, T612), and MEK1/2 (S12, T595) phosphoacceptor residues that control surface expression and dopamine uptake Vmax [#1]. Beyond reuptake, DAT can run in reverse — activation of Gq-coupled receptors drives PKC-dependent DAT-mediated dopamine efflux [#2]. Surface trafficking is further shaped by the GDNF/Ret signaling axis, in which the Rho-family GEF Vav2 is required to regulate DAT surface expression and transport selectively in nucleus accumbens dopamine terminals [#4]. DAT operates within physical complexes: it associates with D2 receptors, whose interaction controls DAT surface expression and protects dopaminergic neurons from dopamine neurotoxicity [#5], and with Kv7.2/7.3 potassium channels, which co-cluster with DAT and readjust membrane potential during transport [#8]. The autism/ADHD-associated coding variant A559V is hyper-phosphorylated, displays constitutively elevated PKCβ activity, resists amphetamine-induced trafficking, and supports anomalous dopamine efflux that is reversed by PKCβ inhibition or N-terminal serine substitution [#3]; in knock-in mice this variant remodels cocaine responses through SERT and 5-HT2C receptor signaling [#9]. At the transcriptional level, the 3'-UTR VNTR acts as an enhancer in dopamine neurons [#0], and 5' promoter haplotypes/SNPs modulate DAT expression with associations to Parkinson's disease and schizophrenia risk [#11, #12]. DAT is also expressed and transport-active outside the nervous system, including renal carcinoma cells under HIF-2α control [#6], blood platelets [#7], and sperm [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established that non-coding regulatory architecture of SLC6A3 controls its transcription in the relevant cell type, framing DAT level as a genetically tunable variable in dopamine neurons.\",\n      \"evidence\": \"Reporter assays of the 3'-UTR 9-repeat VNTR via lipid and biolistic transfection in dopaminergic cell lines and primary midbrain neurons\",\n      \"pmids\": [\"11739616\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not identify the trans-acting factors binding the VNTR\", \"Enhancer activity in immortalized/primary cells may not reflect in vivo expression magnitude\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved how DAT activity is post-translationally controlled by mapping distinct N-terminal phosphoacceptor sites to specific kinase cascades, defining the molecular substrate for activity regulation.\",\n      \"evidence\": \"Mutagenesis of 20 N-terminal sites with kinase inhibitors/activators, dopamine uptake assays, and 32P-labeling\",\n      \"pmids\": [\"12660249\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Performed in heterologous expression, not native dopamine terminals\", \"Does not establish the trafficking machinery downstream of phosphorylation\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed DAT can function in reverse, linking Gq/PKC signaling to dopamine efflux and establishing the transporter as a bidirectional, signal-regulated conduit.\",\n      \"evidence\": \"Amperometry in rat substantia nigra slices and HPLC in cells with Gq-receptor and PKC pharmacology\",\n      \"pmids\": [\"20477913\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify which N-terminal PKC site mediates efflux in this context\", \"Physiological trigger for endogenous Gq-driven efflux unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placed DAT surface regulation within an in vivo GDNF/Ret/Vav2 signaling pathway with regional specificity, connecting extracellular trophic signaling to transporter availability and behavior.\",\n      \"evidence\": \"Vav2-/- and Ret-/- knockout mice with DAT surface assays, dopamine measurements, and cocaine behavior\",\n      \"pmids\": [\"26147533\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between Vav2 GEF activity and DAT trafficking not resolved\", \"Restricted to nucleus accumbens terminals; striatal generality untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated that the D2R–DAT physical complex regulates DAT surface expression and modulates dopamine neurotoxicity, defining a receptor-transporter functional unit.\",\n      \"evidence\": \"Interfering peptide (DAT-S1) disruption with surface expression, caspase-3/PARP-1 cleavage, and neurotoxicity assays\",\n      \"pmids\": [\"28579325\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interface residues mediating the complex not mapped\", \"Neuroprotection shown in model system, not in vivo disease context\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified Kv7.2/7.3 channels as DAT partners that couple transport-associated depolarization to membrane potential recovery, linking electrogenic transport to channel activity.\",\n      \"evidence\": \"BioID, reciprocal Co-IP in HEK293, co-transfection imaging in neurons, uptake assays, and electrophysiology\",\n      \"pmids\": [\"30885609\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry and direct interface of the DAT–Kv7 complex unknown\", \"In vivo functional consequence of the coupling untested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Connected a disease coding variant (A559V) to dysregulated PKCβ-dependent trafficking and anomalous efflux, providing a mechanistic basis for transporter dysfunction in neuropsychiatric disease.\",\n      \"evidence\": \"Surface biotinylation/trafficking, PKCβ activity assays, N-terminal serine mutagenesis, and efflux measurements in transfected cells\",\n      \"pmids\": [\"25313507\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which A559V constitutively activates PKCβ unresolved\", \"Heterologous-cell findings require native-neuron confirmation\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Revealed that the A559V variant remodels psychostimulant responses through SERT and 5-HT2C signaling independent of striatal DA release, broadening the circuit-level consequences of a DAT variant.\",\n      \"evidence\": \"DAT Val559 knock-in mice with fluoxetine/5-HT2C/RTI-113 pharmacology, locomotor assays, and DA microdialysis\",\n      \"pmids\": [\"30578419\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How a DAT variant engages serotonergic signaling mechanistically is unexplained\", \"Single knock-in line, single lab\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Functional promoter haplotype variation under balancing selection was linked to DAT transcriptional activity and Parkinson's disease risk with gene-environment interaction, extending regulatory control to disease susceptibility.\",\n      \"evidence\": \"Haplotype reporter transfection in dopaminergic cells, population genetics, and case-control gene-environment association\",\n      \"pmids\": [\"16963468\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal SNP within haplotype clades not isolated\", \"Association does not establish DAT level as the disease driver\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked elevated nigral DAT mRNA to schizophrenia risk and provided a functional promoter SNP (rs1478435) mechanism, reinforcing transcriptional dosage as a disease-relevant axis.\",\n      \"evidence\": \"Postmortem qPCR in nigral DA neurons, promoter-reporter assay, and case-control association\",\n      \"pmids\": [\"26707863\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direction of causality between DAT expression and disease unproven\", \"Other promoter elements not surveyed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed DAT is functionally expressed outside the nervous system and is transcriptionally controlled by HIF-2α in renal carcinoma, indicating a hypoxia-regulated context for transporter expression.\",\n      \"evidence\": \"[3H]-dopamine uptake, HIF-1α/HIF-2α siRNA knockdown, and hypoxia treatment in ccRCC cells\",\n      \"pmids\": [\"27663598\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Biological role of dopamine uptake in renal cancer unclear\", \"Direct vs indirect HIF-2α regulation of SLC6A3 not distinguished\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Proposed that atypical DAT inhibitors act as pharmacochaperones rescuing ER-retained misfolded DAT to the surface, linking inhibitor binding mode to folding correction.\",\n      \"evidence\": \"Mechanistic synthesis of pharmacochaperoning and ER retention/surface expression experiments (review)\",\n      \"pmids\": [\"31064865\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Review without primary data in this entry\", \"Structural basis of chaperone binding to folding intermediates not directly demonstrated here\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How phosphorylation, trophic signaling, and the D2R/Kv7 complexes are integrated to set DAT surface density and direction of transport in native dopamine terminals remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural/biochemical model linking N-terminal phosphosites to specific trafficking machinery\", \"Interfaces of DAT physical complexes not mapped\", \"In vivo causal contribution of transcriptional variants to disease unestablished\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [1, 2, 6, 7, 10]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [1, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 3, 4, 5, 8]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [1, 6]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 4, 5]}\n    ],\n    \"complexes\": [\n      \"D2R–DAT complex\",\n      \"DAT–Kv7.2/7.3 complex\"\n    ],\n    \"partners\": [\n      \"DRD2\",\n      \"KCNQ2\",\n      \"KCNQ3\",\n      \"VAV2\",\n      \"RET\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}